Search

Your search keyword '"Frommert, Leonie Maria"' showing total 8 results
Start Over Author "Frommert, Leonie Maria"
8 results on '"Frommert, Leonie Maria"'

2. Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease

Author

Frommert, Leonie Maria, primary, Arumahandi de Silva, Amanthi Nadira, additional, Zernicke, Jan, additional, Scholz, Veronika, additional, Braun, Tanja, additional, Jeworowski, Lara Maria, additional, Schwarz, Tatjana, additional, Tober-Lau, Pinkus, additional, ten Hagen, Alexander, additional, Habermann, Elisa, additional, Kurth, Florian, additional, Sander, Leif Erik, additional, Corman, Victor Max, additional, Burmester, Gerd-Rüdiger, additional, Biesen, Robert, additional, Albach, Fredrik N., additional, and Klotsche, Jens, additional

Published
2022
Full Text
View/download PDF

3. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination

Author

Habermann, Elisa, primary, Gieselmann, Lutz, additional, Tober-Lau, Pinkus, additional, Klotsche, Jens, additional, Albach, Fredrik Nils, additional, ten Hagen, Alexander, additional, Zernicke, Jan, additional, Ahmadov, Elvin, additional, Arumahandi de Silva, Amanthi Nadira, additional, Frommert, Leonie Maria, additional, Kurth, Florian, additional, Sander, Leif Erik, additional, Burmester, Gerd R, additional, Klein, Florian, additional, and Biesen, Robert, additional

Published
2022
Full Text
View/download PDF

4. Impaired Neutralization of SARS-CoV-2 Including Omicron Variants after COVID-19 mRNA Booster Immunization under Methotrexate Therapy.

Author

Habermann, Elisa, primary, Gieselmann, Lutz, additional, Tober-Lau, Pinkus, additional, ten Hagen, Alexander, additional, Albach, Fredrik N., additional, Zernicke, Jan, additional, Ahmadov, Elvin, additional, Klotsche, Jens, additional, Arumahandi de Silva, Amanthi Nadira, additional, Frommert, Leonie Maria, additional, Kurth, Florian, additional, Sander, Leif, additional, Burmester, Gerd-Ruediger, additional, Klein, Florian, additional, and Biesen, Robert, additional

Published
2022
Full Text
View/download PDF

5. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination

Author

Habermann, Elisa, Gieselmann, Lutz, Tober-Lau, Pinkus, Klotsche, Jens, Albach, Fredrik Nils, Ten Hagen, Alexander, Zernicke, Jan, Ahmadov, Elvin, de Silva, Amanthi Nadira Arumahandi, Frommert, Leonie Maria, Kurth, Florian, Sander, Leif Erik, Burmester, Gerd R., Klein, Florian, Biesen, Robert, Habermann, Elisa, Gieselmann, Lutz, Tober-Lau, Pinkus, Klotsche, Jens, Albach, Fredrik Nils, Ten Hagen, Alexander, Zernicke, Jan, Ahmadov, Elvin, de Silva, Amanthi Nadira Arumahandi, Frommert, Leonie Maria, Kurth, Florian, Sander, Leif Erik, Burmester, Gerd R., Klein, Florian, and Biesen, Robert

Abstract

Objective The level of neutralising capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is unclear. Methods In this observational cohort study, neutralising serum activity against SARS-CoV-2 wild-type (Wu01) and variant of concern Omicron BA.1 and BA.2 were assessed by pseudovirus neutralisation assay before, 4 and 12 weeks after mRNA booster immunisation in 50 rheumatic patients on MTX, 26 of whom paused the medication. 44 non-immunosuppressed persons (NIP) served as control group. Results While the neutralising serum activity against SARS-CoV-2 Wu01 and Omicron variants increased 67-73 fold in the NIP after booster vaccination, the serum activity in patients receiving MTX increased only 20-23 fold. Patients who continued MTX treatment during vaccination had significantly lower neutralisation against all variants at weeks 4 and 12 compared with patients who paused MTX and the control group, except for BA.2 at week 12. Patients who paused MTX reached comparably high neutralising capacities as NIP, except for Wu01 at week 12. The duration of the MTX pause after-not before-was associated with a significantly higher neutralisation capacity against all three variants, with an optimal duration at 10 days after vaccination. Conclusion Patients pausing MTX after COVID-19 booster showed a similar vaccine response to NIP. Patients who continued MTX demonstrated an impaired response indicating a potentially beneficial second booster vaccination. Our data also suggest that a 1 week MTX break is sufficient if the last administration of MTX occurs 1-3 days before vaccination.

Published
2022

6. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases

Author

Arumahandi de Silva, Amanthi Nadira, primary, Frommert, Leonie Maria, additional, Albach, Fredrik N, additional, Klotsche, Jens, additional, Scholz, Veronika, additional, Jeworowski, Lara Maria, additional, Schwarz, Tatjana, additional, ten Hagen, Alexander, additional, Zernicke, Jan, additional, Corman, Victor Max, additional, Drosten, Christian, additional, Burmester, Gerd-Rüdiger, additional, and Biesen, Robert, additional

Published
2022
Full Text
View/download PDF

7. Improvement of Humoral Immunity by Repeated Dose-Intensified COVID-19 Vaccinations in Primary Non- to Low-Responders and B Cell Deficient Rheumatic Disease Patients

Author

ten Hagen, Alexander, primary, Hermann, Sandra, additional, Habermann, Elisa, additional, Frommert, Leonie Maria, additional, Arumahandi de Silva, Amanthi Nadira, additional, Scholz, Veronika, additional, Ghannam, Khetam, additional, Klotsche, Jens, additional, Zernicke, Jan, additional, Burmester, Gerd, additional, Albach, Fredrik Nils, additional, and Biesen, Robert, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results